# German Center for Lung Research

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/german-center-for-lung-research/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 73.6 |
| Citations | 1,413,262 |
| City | Giessen |
| Country | DE |
| Description | German Center for Lung Research is a research organisation in Giessen, DE. OpenAlex records 14,442 works and 1,413,262 citations for it. 3,816 researchers list it as their most recent affiliation. |
| Homepage | https://dzl.de |
| OpenAlex ID | https://openalex.org/I4210129183 |
| Region | Hesse |
| Researchers | 3,816 |
| ROR ID | https://ror.org/03dx11k66 |
| Type | facility |
| Works | 14,442 |

## University papers

Showing 12 of 54.

- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for-2/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)

## University researchers

- [Laura Schäfer](https://scholariq.org/researchers/laura-schafer/)

## University top topics

Showing 8 of 25.

- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Neonatal Respiratory Health Research](https://scholariq.org/topics/neonatal-respiratory-health-research/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Pulmonary Hypertension Research and Treatments](https://scholariq.org/topics/pulmonary-hypertension-research-and-treatments/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cystic Fibrosis Research Advances](https://scholariq.org/topics/cystic-fibrosis-research-advances/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.